603122 Cowealth Medical China
- 6.10
- -0.14-2.24%
Cowealth Medical China News
The pharmaceutical business sector fluctuated and picked up. Yu Shu Min rose 20 cm, Dajia Weikang rose more than 15%, and Pharma Tesco, Chinese Health, Inter Group, Hefu China, and Guoke Hengtai followed suit.
The pharmaceutical business sector fluctuated and picked up. Yu Shu Min rose 20 cm, Dajia Weikang rose more than 15%, and Pharma Tesco, Chinese Health, Inter Group, Hefu China, and Guoke Hengtai followed suit.
Cowealth Medical China's Operating Income Falls 11% in January-April
Cowealth Medical China (SHA:603122) recorded a consolidated operating income of between January and April, sliding 11.12% from the prior year. Shares of the company fell nearly 2% in recent trade.
Hefu China (603122.SH): The cumulative consolidated revenue for January-April was 330 million yuan, a year-on-year decrease of 11.12%
On May 9, Ge Longhui China (603122.SH) announced that the company's cumulative consolidated revenue from January to April 2024 was RMB 332.672 million, down 11.12% from the consolidated revenue for the same period last year.
Hefu China (603122.SH) announced first-quarter results, net profit of 7.13 million yuan, a year-on-year decrease of 22.65%
Hefu China (603122.SH) disclosed its report for the first quarter of 2024. The company achieved revenue of 2.3 during the reporting period...
Capital Allocation Trends At Cowealth Medical ChinaLtd (SHSE:603122) Aren't Ideal
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key financial metrics. Firstly, we'll want to see a proven return on capital employ
Express News | Hefu China: Cumulative operating revenue decreased 10.69% year-on-year from January to March 2024
Hefu China (603122.SH): Net profit in 2023 fell 42.96% year on year, and plans to pay 10 0.60 yuan
On March 22, Ge Longhui China (603122.SH) released its 2023 annual report. During the reporting period, it achieved operating income of 1,093 billion yuan, a year-on-year decrease of 14.62%; net profit attributable to shareholders of listed companies was 47,1889 million yuan, a year-on-year decrease of 42.96%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 469.192 million yuan, a year-on-year decrease of 38.18%; and basic earnings per share were 0.12 yuan. On March 22, 2024, the board of directors of the company proposed that the company distribute cash dividends to common shareholders to implement the equity registration date
A-share SPD concept stocks fluctuated and rose, and Hefu China went up and down in a straight line
Gelonghui, March 18 | Hefu China went up and down in a straight line. Saili Medical was previously closed, and Runda Healthcare, Guoxin Health, Kaikai Industrial, and Zhejiang Zhenyuan followed suit.
Hefu China (603122.SH) has accumulated consolidated revenue of about 150 million yuan in the first 2 months
Hefu China (603122.SH) announced that the company's cumulative consolidated revenue for January-February 2024 was 1.5...
Express News | Hefu China: The cumulative consolidated revenue for January-February was 1.2% year-on-year increase in RMB
Hefu China (603122.SH): Zhang Chen resigns as financial director
Hefu China (603122.SH) issued an announcement. Du Jiahai, the company's deputy general manager, and Zhang Chen, deputy general manager and financial director...
Is Cowealth Medical China Co.,Ltd.'s (SHSE:603122) Stock On A Downtrend As A Result Of Its Poor Financials?
Cowealth Medical ChinaLtd (SHSE:603122) has had a rough three months with its share price down 24%. We decided to study the company's financials to determine if the downtrend will continue as the lo
The A-share pharmaceutical commercial sector fluctuated and rose, and Hefu China directly rose and stopped
Gelonghui, Feb. 20 | Hefu China went up and down in a straight line, opening up more than 8%, while Guoke Hengtai, Saili Healthcare, Dajia Weikang, and Chinese Health followed suit.
Express News | Hefu China: Consolidated revenue increased 13.58% year-on-year in January
Hefu China (603122.SH): Consolidated revenue of 1,099 billion yuan from January to December 2023 decreased by 14.11% year-on-year
On January 10, Gelonghui China (603122.SH) announced that the company's consolidated revenue for January-December 2023 was RMB 1,099 billion, down 14.11% from the consolidated revenue for the same period last year.
Hefu China (603122.SH): January-November consolidated revenue of 982 million yuan decreased 14.75% year-on-year
Hefu China (603122.SH) announced that the company's consolidated revenue from January to November 2023 was RMB 9...
Hefu China (603122.SH): Consolidated revenue from January to October was 910 million yuan, a year-on-year decrease of 13.47%
Hefu China (603122.SH) announced that the company's consolidated operating income from January to October 2023 is for the people...
Hefu China (603122.SH): Net profit of 44.07 million yuan in the first three quarters fell 18.77% year-on-year
Glonghui, October 26丨Hefu China (603122.SH) announced its third quarter report. Revenue was 833 million yuan, down 12.88% year on year, net profit was 44.07 million yuan, down 18.77% year on year, net profit was 44.07 million yuan, down 18.77% year on year, after deducting non-net profit of 39.076 million yuan, down 26.85% year on year, and basic earnings per share were 0.11 yuan.
Hefu China (603122.SH): January-September consolidated revenue decreased by 12.88% year-on-year
Glonghui, Oct. 11丨Hefu China (603122.SH) announced that the company's consolidated revenue from January to September 2023 was RMB 833 million, a decrease of 12.88% over the same period last year.
Hefu China (603122.SH): Consolidated revenue of 833 million yuan from January to September decreased by 12.88% year-on-year
Hefu China (603122.SH) announced that the company's consolidated operating income from January to September 2023 was RMB...
Analysis
Price Target
No Data
